Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification.
Human papillomavirus (HPV) E6/E7 mRNA has been proposed as a more specific marker for cervical dysplasia and cancer than HPV DNA. This study evaluated the RNA specificity of nucleic acid sequence-based amplification (NASBA)-based HPV detection using HPV DNA plasmids (HPV type 16 [HPV16], HPV18, HPV31, HPV33, and HPV45) and nucleic acid extracts of several cell lines, which were systematically subjected to enzymatic treatments with DNase and RNase. HPV plasmid dilutions (10(6) to 10(0) copies/microl) and nucleic acid extracts (total DNA, RNA-free DNA, total RNA, and DNA-free RNA) of unfixed and fixed (PreServCyt and SurePath) HaCaT, HeLa, and CaSki cells were tested with the NucliSENS EasyQ HPV test. The RNA-free DNA extracts of HeLa and CaSki cells could be amplified by HPV18 and -16 NASBA, respectively. Fixation of the cells did not influence NASBA. All HPV plasmids could be detected with NASBA. Based on the plasmid dilution series, a lower detection limit of 5 x 10(3) HPV DNA copies could be determined. Our study identified viral double-stranded DNA as a possible target for NASBA-based HPV detection. The differences in diagnostic accuracy between the NASBA-based tests and conventional HPV DNA detection assays seem to be attributable not to the more specific amplification of viral mRNA but to the limited type range and the lower analytical sensitivity for HPV DNA.
Boulet
Gaëlle A V
GA
University of Antwerp, Laboratory for Cell Biology and Histology, Antwerp, Belgium. gaelle.boulet@ua.ac.be
Micalessi
Isabel M
IM
Horvath
Caroline A J
CA
Benoy
Ina H
IH
Depuydt
Christophe E
CE
Bogers
Johannes J
JJ
D052685:Alphapapillomavirus / Q000145:classification / Q000235:genetics; D045744:Cell Line, Tumor; D004279:DNA, Viral / Q000032:analysis / Q000302:isolation & purification; D006367:HeLa Cells; D006801:Humans; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D030361:Papillomavirus Infections / Q000821:virology; D010957:Plasmids / Q000235:genetics; D012367:RNA, Viral / Q000032:analysis / Q000302:isolation & purification*; D015203:Reproducibility of Results; D014773:Virology / Q000379:methods*
D004279:DNA, Viral; D012367:RNA, Viral
Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34
16950015
J Mol Diagn. 2006 Feb;8(1):113-8
16436642
J Clin Microbiol. 2009 Dec;47(12):3895-901
19828739
Vaccine. 2008 Aug 19;26 Suppl 10:K42-52
18847556
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3033-42
18957520
J Clin Pathol. 2008 Jan;61(1):132-7
17468293
J Clin Microbiol. 2009 Aug;47(8):2458-64
19535524
Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S230-2
17822751
J Clin Virol. 2009 Jul;45 Suppl 1:S29-37
19651366
J Med Virol. 2004 Sep;74(1):107-16
15258976
Vaccine. 2008 Aug 19;26 Suppl 10:K29-41
18847555
Cytopathology. 2006 Dec;17(6):374-81
17168921
Cancer. 2002 Apr 15;94(8):2199-210
12001118
Gynecol Oncol. 2005 Jun;97(3):908-15
15943992
Mol Cell Probes. 2004 Aug;18(4):251-3
15271385
Cancer Treat Rev. 2004 Apr;30(2):205-11
15023438
Vaccine. 2008 Aug 19;26 Suppl 10:K62-7
18847558
Obstet Gynecol Surv. 2004 Jul;59(7):543-53
15199273
J Clin Pathol. 2002 Apr;55(4):244-65
11919208
J Natl Cancer Inst. 2004 Feb 18;96(4):280-93
14970277
Gynecol Oncol. 1995 Feb;56(2):239-44
7896192
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S7-11
16154623
Mol Biotechnol. 2002 Feb;20(2):163-79
11876473
N Engl J Med. 2007 Oct 18;357(16):1589-97
17942872
J Med Virol. 2004 May;73(1):65-70
15042650
J Virol Methods. 2009 Jan;155(1):61-6
18955086
Biotechniques. 2000 Aug;29(2):236-8, 240
10948422
J Cell Mol Med. 2007 Jul-Aug;11(4):881-91
17760847
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):810-7
18398022
J Clin Microbiol. 2006 Apr;44(4):1310-7
16597856
J Natl Cancer Inst. 2000 Mar 1;92(5):397-402
10700419
J Virol Methods. 2007 Jun;142(1-2):204-12
17379322
J Med Virol. 2000 Oct;62(2):251-8
11002256
J Clin Microbiol. 2001 Oct;39(10):3656-65
11574587
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72
15734959
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45
18842994
Int J Cancer. 2005 May 10;114(6):973-6
15645423
J Virol Methods. 2006 Oct;137(1):58-62
16828171
J Virol. 2003 Oct;77(19):10186-201
12970404
J Clin Microbiol. 2009 Jul;47(7):2136-41
19403762
J Clin Microbiol. 2000 Feb;38(2):651-5
10655362